Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Net cash floor and Analyst consensus.
ACCE opinionEntrada Therapeutics Inc. Common Stock (TRDA)
Fair value
Not available
ACCE price target
$4.70
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $4.41 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
21
out of 100
Analysts
88% buy
8 covering
P/E
0.0x
forward 3333.3x
1-year return
-31.1%
Dividend yield
0.00%
Entrada Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Entrada Therapeutics is a clinical-stage biotech developing cell-penetrating peptide platforms to deliver oligonucleotide and protein therapeutics into cells, with its lead programs aimed at muscle and central nervous system disease. Its appeal rests on the delivery technology itself, which is the bottleneck that has kept many nucleic-acid drugs from reaching tissues beyond the liver. The data we have, though, shows no revenue to speak of: reported revenue fell 53.9% year over year, gross margin sits near minus 2,867%, and operating margin near minus 5,007%, so the company is funded by its balance sheet and partnerships rather than sales. The scorecard reads 23 out of 100 and the stock is outside any index, which suggests the market is pricing in substantial clinical and financing risk. This merits a deeper look only if the pipeline readouts and cash runway can be checked against the company's own filings.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
severe
Free cash burn
Free cash flow is -$129.6M against a $177M market cap, so the company is consuming roughly 73% of its equity value in a single period. Cash runway is a live question.
high
Revenue collapse
Revenue is down 53.9% year over year, while operating margin is -5007.0% and gross margin is -2867.2%. Costs far exceed sales.
high
Heavy insider selling
Insiders disclosed $6.96M in sales against only $0.03M in buys across the last 10 filings. Insider selling outweighs insider buying by a wide margin.
moderate
Elevated short interest
Short interest sits at 11.9% of the float, meaning a meaningful share of holders are betting on further decline. Expect volatility around any news.
AI research notes
AI-assisted·How I use AIWritten Oct 15, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Seven of eight analysts rate the stock Buy or Strong Buy, and their average target sits well above the current price.
Earnings per share came in better than expected in the latest quarter, with a loss of $1.01 against a forecast of $1.16.
Debt is modest relative to equity, with debt at 0.17 times equity, so the balance sheet is not weighed down by borrowing.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$130M, so the business is consuming cash rather than generating it.
Revenue fell 53.9% year over year, and the company still reports a net margin of 0.0%.
Return on equity of -54.1% shows shareholders' capital is being eroded, and the share count has also grown by 6.1%.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TRDA's valuation models land
Price
$4.41
Model fair valueConfidence: low
about $10.74
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores